Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page revision label was updated to Revision: v3.5.2, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check36 days agoChange DetectedAdded revision: v3.5.0; deleted revision: v3.4.3.SummaryDifference0.1%

- Check43 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2 to reflect the page's latest version.SummaryDifference0.1%

- Check72 days agoChange DetectedRevision: v3.4.2 has been added, and the funding-lapse notice has been removed. This update does not modify study content, eligibility criteria, or outcomes.SummaryDifference0.4%

- Check79 days agoChange DetectedThe page now shows a government funding notice regarding potential delays and open status of the NIH Clinical Center, and the site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check86 days agoChange DetectedMinor UI/metadata updates were made: the glossary option is now shown, revision labels were updated to Revision: v3.4.0 with capitalization tweaks for No FEAR Act data, and older labels such as 'Last Update Submitted that met QC Criteria' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.